Correction to: Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study (International Journal of Clinical Oncology, (2022), 27, 12, (1828-1838), 10.1007/s10147-022-02232-7)

Shunichi Sugawara; Masashi Kondo; Toshihide Yokoyama; Toru Kumagai; Makoto Nishio; Koichi Goto; Kazuhiko Nakagawa; Takashi Seto; Nobuyuki Yamamoto; Kentarou Kudou; Takayuki Asato; Pingkuan Zhang; Yuichiro Ohe

doi:10.1007/s10147-022-02286-7

Correction to: Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study (International Journal of Clinical Oncology, (2022), 27, 12, (1828-1838), 10.1007/s10147-022-02232-7)

Shunichi Sugawara
, Masashi Kondo
, Toshihide Yokoyama
, Toru Kumagai
, Makoto Nishio
, Koichi Goto
, Kazuhiko Nakagawa
, Takashi Seto
, Nobuyuki Yamamoto
, Kentarou Kudou
, Takayuki Asato
, Pingkuan Zhang
, Yuichiro Ohe

研究成果: ジャーナルへの寄稿 › コメント/討論 › 査読

抄録

In the original publication, under section: Secondary end points, the sentence starting with: “KM estimated...” should read as: KM estimated median DoR was not reached (95% CI 13.9–not reached) in patients who had confirmed responses. The original publication has been corrected.

本文言語	英語
ページ（範囲）	724-725
ページ数	2
ジャーナル	International Journal of Clinical Oncology
巻	28
号	5
DOI	https://doi.org/10.1007/s10147-022-02286-7
出版ステータス	出版済み - 05-2023
外部発表	はい

UN SDG

この成果は、次の持続可能な開発目標に貢献しています

SDG 3 すべての人に健康と福祉を

All Science Journal Classification (ASJC) codes

外科
血液学
腫瘍学

文献へのアクセス

10.1007/s10147-022-02286-7

他のファイルとリンク

フィンガープリント

「Correction to: Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study (International Journal of Clinical Oncology, (2022), 27, 12, (1828-1838), 10.1007/s10147-022-02232-7)」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル

Sugawara, S., Kondo, M., Yokoyama, T., Kumagai, T., Nishio, M., Goto, K., Nakagawa, K., Seto, T., Yamamoto, N., Kudou, K., Asato, T., Zhang, P., & Ohe, Y. (2023). Correction to: Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study (International Journal of Clinical Oncology, (2022), 27, 12, (1828-1838), 10.1007/s10147-022-02232-7). International Journal of Clinical Oncology, 28(5), 724-725. https://doi.org/10.1007/s10147-022-02286-7

Sugawara, Shunichi ; Kondo, Masashi ; Yokoyama, Toshihide その他. / Correction to : Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study (International Journal of Clinical Oncology, (2022), 27, 12, (1828-1838), 10.1007/s10147-022-02232-7). In: International Journal of Clinical Oncology. 2023 ; Vol. 28, No. 5. pp. 724-725.

@article{f13882e2ad0b4ca99ac95e04cd1448f7,

title = "Correction to: Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study (International Journal of Clinical Oncology, (2022), 27, 12, (1828-1838), 10.1007/s10147-022-02232-7)",

abstract = "In the original publication, under section: Secondary end points, the sentence starting with: {\textquotedblleft}KM estimated...{\textquotedblright} should read as: KM estimated median DoR was not reached (95\% CI 13.9{\textendash}not reached) in patients who had confirmed responses. The original publication has been corrected.",

author = "Shunichi Sugawara and Masashi Kondo and Toshihide Yokoyama and Toru Kumagai and Makoto Nishio and Koichi Goto and Kazuhiko Nakagawa and Takashi Seto and Nobuyuki Yamamoto and Kentarou Kudou and Takayuki Asato and Pingkuan Zhang and Yuichiro Ohe",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2023.",

year = "2023",

month = may,

doi = "10.1007/s10147-022-02286-7",

language = "English",

volume = "28",

pages = "724--725",

journal = "International Journal of Clinical Oncology",

issn = "1341-9625",

publisher = "Springer",

number = "5",

}

Sugawara, S, Kondo, M, Yokoyama, T, Kumagai, T, Nishio, M, Goto, K, Nakagawa, K, Seto, T, Yamamoto, N, Kudou, K, Asato, T, Zhang, P & Ohe, Y 2023, 'Correction to: Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study (International Journal of Clinical Oncology, (2022), 27, 12, (1828-1838), 10.1007/s10147-022-02232-7)', International Journal of Clinical Oncology, vol. 28, no. 5, pp. 724-725. https://doi.org/10.1007/s10147-022-02286-7

Correction to: Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study (International Journal of Clinical Oncology, (2022), 27, 12, (1828-1838), 10.1007/s10147-022-02232-7). / Sugawara, Shunichi; Kondo, Masashi; Yokoyama, Toshihide その他.
In: International Journal of Clinical Oncology, Vol. 28, No. 5, 05.2023, p. 724-725.

研究成果: ジャーナルへの寄稿 › コメント/討論 › 査読

TY - JOUR

T1 - Correction to

T2 - Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study (International Journal of Clinical Oncology, (2022), 27, 12, (1828-1838), 10.1007/s10147-022-02232-7)

AU - Sugawara, Shunichi

AU - Kondo, Masashi

AU - Yokoyama, Toshihide

AU - Kumagai, Toru

AU - Nishio, Makoto

AU - Goto, Koichi

AU - Nakagawa, Kazuhiko

AU - Seto, Takashi

AU - Yamamoto, Nobuyuki

AU - Kudou, Kentarou

AU - Asato, Takayuki

AU - Zhang, Pingkuan

AU - Ohe, Yuichiro

PY - 2023/5

Y1 - 2023/5

N2 - In the original publication, under section: Secondary end points, the sentence starting with: “KM estimated...” should read as: KM estimated median DoR was not reached (95% CI 13.9–not reached) in patients who had confirmed responses. The original publication has been corrected.

AB - In the original publication, under section: Secondary end points, the sentence starting with: “KM estimated...” should read as: KM estimated median DoR was not reached (95% CI 13.9–not reached) in patients who had confirmed responses. The original publication has been corrected.

UR - https://www.scopus.com/pages/publications/85146383213

UR - https://www.scopus.com/pages/publications/85146383213#tab=citedBy

U2 - 10.1007/s10147-022-02286-7

DO - 10.1007/s10147-022-02286-7

M3 - Comment/debate

C2 - 36648711

AN - SCOPUS:85146383213

SN - 1341-9625

VL - 28

SP - 724

EP - 725

JO - International Journal of Clinical Oncology

JF - International Journal of Clinical Oncology

IS - 5

ER -

Sugawara S, Kondo M, Yokoyama T, Kumagai T, Nishio M, Goto K その他. Correction to: Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study (International Journal of Clinical Oncology, (2022), 27, 12, (1828-1838), 10.1007/s10147-022-02232-7). International Journal of Clinical Oncology. 2023 5月;28(5):724-725. doi: 10.1007/s10147-022-02286-7